Literature DB >> 1638535

Inhibition of proliferation by c-myb antisense RNA and oligodeoxynucleotides in transformed neuroectodermal cell lines.

G Raschellà1, A Negroni, T Skorski, S Pucci, M Nieborowska-Skorska, A Romeo, B Calabretta.   

Abstract

Transfection of a neuroblastoma cell line with expression vectors containing two different segments of human c-myb complementary DNA in antisense orientation yielded far fewer transfectant clones than did the transfection with the identical segments in sense orientation. In cell clones expressing c-myb antisense RNA, levels of the c-myb protein were down-regulated and the proliferation rate was slower than that of cells transfected with sense constructs or the untransfected parental cell line. Treatment of neuroblastoma and neuroepithelioma cell lines with a c-myb antisense oligodeoxynucleotide strongly inhibited cell growth. These data indicate a definite involvement of c-myb in the proliferation of neuroectodermal tumor cells extending the role of this protooncogene beyond the hematopoietic system. The availability of cell clones that transcribe c-myb antisense RNA provides a useful tool to study the involvement of other genes in the proliferation and differentiation of neuroblastoma cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1638535

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

Review 1.  Retinoids and the control of growth/death decisions in human neuroblastoma cell lines.

Authors:  G Melino; C J Thiele; R A Knight; M Piacentini
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

2.  Phenotypic and morphological characterization of neuroblastoma cells constitutively expressing B-myb.

Authors:  S Scarpa; A Negroni; R Amendola; P Signorelli; B Calabretta; A Modesti; G Raschellà
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

3.  Expression of Slug is regulated by c-Myb and is required for invasion and bone marrow homing of cancer cells of different origin.

Authors:  Barbara Tanno; Fabiola Sesti; Vincenzo Cesi; Gianluca Bossi; Giovanna Ferrari-Amorotti; Rita Bussolari; Donatella Tirindelli; Bruno Calabretta; Giuseppe Raschellà
Journal:  J Biol Chem       Date:  2010-07-11       Impact factor: 5.157

4.  Overexpression of C-terminally but not N-terminally truncated Myb induces fibrosarcomas: a novel nonhematopoietic target cell for the myb oncogene.

Authors:  R D Press; E P Reddy; D L Ewert
Journal:  Mol Cell Biol       Date:  1994-04       Impact factor: 4.272

5.  Effect of cisplatin and c-myb antisense phosphorothioate oligodeoxynucleotides combination on a human colon carcinoma cell line in vitro and in vivo.

Authors:  D Del Bufalo; C Cucco; C Leonetti; G Citro; I D'Agnano; M Benassi; T Geiser; G Zon; B Calabretta; G Zupi
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

Review 6.  Reassessing the Potential of Myb-targeted Anti-cancer Therapy.

Authors:  Xiaofeng Liu; Yunxiao Xu; Liping Han; Yan Yi
Journal:  J Cancer       Date:  2018-03-15       Impact factor: 4.207

7.  Transcriptional regulation of mouse PXR gene: an interplay of transregulatory factors.

Authors:  Sangeeta Kumari; Gauranga Mukhopadhyay; Rakesh K Tyagi
Journal:  PLoS One       Date:  2012-08-28       Impact factor: 3.240

8.  Regulation of proliferation and cytokine expression of bone marrow fibroblasts: role of c-myb.

Authors:  C Szczylik; T Skorski; D H Ku; N C Nicolaides; S C Wen; L Rudnicka; A Bonati; L Malaguarnera; B Calabretta
Journal:  J Exp Med       Date:  1993-09-01       Impact factor: 14.307

9.  MYCN is amplified during S phase, and c‑myb is involved in controlling MYCN expression and amplification in MYCN‑amplified neuroblastoma cell lines.

Authors:  Nevim Aygun; Oguz Altungoz
Journal:  Mol Med Rep       Date:  2018-11-22       Impact factor: 2.952

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.